NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions

Type 1 DiabetesLipoatrophy

Interventions

DRUG

Apidra

Half of patients with lipoatrophy will be switched randomly to insulin Apidra for 12 months. Any site other than the lipoatrophic site would be used for delivering the insulin for the purpose of this study.

DRUG

current insulin

Half of patients with lipoatrophy will still use their current Insulin for 6 months. After 6 months the current insulin will be switched to insulin Apidra for the next 6 months.